Legend Biotech (LEGN) Gross Margin (2022 - 2026)

Legend Biotech (LEGN) has 5 years of Gross Margin data on file, last reported at 42.51% in Q1 2026.

• Quarterly Gross Margin fell 2185.0% year-over-year to 42.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 50.44% (down 1704.0% YoY) and the FY2024 annual result came in at 65.51%, up 1608.0% from the prior year.
• Gross Margin declined to 42.51% in Q1 2026, from 58.41% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 99.96% in Q4 2023 to a low of 1.99% in Q1 2023.
• A 5-year average of 51.25% and a median of 56.93% in 2023 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2023 — Gross Margin jumped 8306 bps — and 2024, when it tumbled 3717 bps.
• Tracing LEGN's Gross Margin over 5 years: stood at 16.9% in 2022, then jumped by 492 bps to 99.96% in 2023, then plunged by 37 bps to 62.79% in 2024, then retreated by 7 bps to 58.41% in 2025, then decreased by 27 bps to 42.51% in 2026.
• The last three Gross Margin figures came in at 42.51% (Q1 2026), 58.41% (Q3 2025), and 62.8% (Q2 2025), per Business Quant data.